AIRS Medical Named Finalist in the 2026 Digital Health & AI Awards

AIRS Medical advances to the finals in the Best in Class – Healthy Lifespan, Longevity & Prevention category, recognizing its work in consistent quantitative brain MRI through SwiftSight®.

AIRS Medical named Best in Class finalist in the 2026 Digital Health & AI Awards, Healthy Lifespan, Longevity & Prevention category

CHICAGO — October 19, 2026 — AIRS Medical, a global AI medical imaging company, has been named a Finalist in the 2026 Digital Health & AI Awards, presented by the Digital Health Hub Foundation, in the Best in Class Track – Healthy Lifespan, Longevity & Prevention category.

The recognition marks AIRS Medical’s advancement from Quarterfinalist to Finalist in a competition that attracted more than 1,300 participating companies worldwide.

The Digital Health & AI Awards recognize organizations advancing healthcare through digital innovation and artificial intelligence, including technologies supporting prevention, healthier aging and improved patient outcomes.

Advancing Consistent Quantitative MRI for Brain Health

Understanding how the brain changes over time requires more than high-quality imaging. It requires quantitative measurements that remain consistent across scanners, imaging environments and follow-up examinations.

SwiftSight®, AIRS Medical’s AI-powered quantitative brain imaging solution, is designed to reduce measurement variability and support more confident longitudinal brain assessment.

By delivering reproducible brain measurements across scanner vendors and field strengths, SwiftSight® helps clinicians evaluate structural brain changes over time with greater confidence. Its quantitative approach supports the growing role of MRI in monitoring brain health, understanding age-related changes and informing longitudinal patient assessment.

“Understanding brain health over time requires measurements clinicians can trust,” said Jina Park, Chief Strategy Officer at AIRS Medical. “With SwiftSight, we’re working to make quantitative MRI more consistent across scanners so clinicians can focus on measuring the patient, not the scanner. Advancing to the finals is meaningful recognition of our team’s work and our vision for more reliable longitudinal brain assessment.”

Recognizing Innovation in Digital Health and AI

From more than 1,300 participating companies, finalists were selected through successive rounds of evaluation across the Digital Health & AI Awards’ Rising Star and Best in Class tracks.

“The transition from Quarterfinalist to Finalist is where the competition really gets exciting,” said Mark H. Goldstein, Chairman of the Digital Health Hub Foundation. “We’re seeing companies move beyond promising ideas to solutions that are changing how healthcare is delivered, experienced, and accessed. Our finalists represent an extraordinary range of innovation, and we can’t wait to bring their achievements to the stage at HLTH in November.”

The Road to HLTH 2026

The 2026 Digital Health & AI Awards will culminate on Monday, November 16, at HLTH USA at The Venetian in Las Vegas, where Rising Star and Best in Class winners will be announced live.

AIRS Medical’s category, Healthy Lifespan, Longevity & Prevention, will be featured during The Future of Health & Intelligent Care awards program, scheduled for 5:00 PM.

About the Digital Health & AI Awards

The Digital Health & AI Awards are presented by the Digital Health Hub Foundation, a nonprofit organization focused on identifying, recognizing and elevating companies and innovations shaping the future of healthcare.

Founded in 2017 on the UCSF campus in San Francisco, the Foundation brings together healthcare innovators, clinicians, researchers, investors, technology leaders and other members of the healthcare ecosystem.

Learn more at digitalhealthhub.org.

About AIRS Medical

AIRS Medical is a global AI medical imaging company transforming MRI through deep learning. Its solutions, SwiftMR® and SwiftSight®, are deployed at leading health systems and imaging networks worldwide. SwiftMR® is FDA-cleared, CE-marked under MDR, and approved by Korea’s MFDS, Japan’s PMDA, and other regulatory authorities across 40+ countries. Learn more at airsmed.com.

Media Contact

Cynthia Ruffino
Vice President, Marketing
media@airsmed.com

Related reading:
AIRS Medical Named Quarterfinalist in the 2026 Digital Health & AI Awards